Logo image of MDGL

MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Fundamental Analysis

USA - NASDAQ:MDGL - US5588681057 - Common Stock

558.415 USD
-0.58 (-0.1%)
Last: 11/19/2025, 2:58:22 PM
Fundamental Rating

3

MDGL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. The financial health of MDGL is average, but there are quite some concerns on its profitability. MDGL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MDGL had negative earnings in the past year.
In the past year MDGL has reported a negative cash flow from operations.
MDGL had negative earnings in each of the past 5 years.
In the past 5 years MDGL always reported negative operating cash flow.
MDGL Yearly Net Income VS EBIT VS OCF VS FCFMDGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -21.22%, MDGL is in the better half of the industry, outperforming 75.05% of the companies in the same industry.
MDGL has a better Return On Equity (-46.21%) than 67.73% of its industry peers.
Industry RankSector Rank
ROA -21.22%
ROE -46.21%
ROIC N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
MDGL Yearly ROA, ROE, ROICMDGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

MDGL's Gross Margin of 95.25% is amongst the best of the industry. MDGL outperforms 94.56% of its industry peers.
MDGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDGL Yearly Profit, Operating, Gross MarginsMDGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

MDGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MDGL has been increased compared to 1 year ago.
Compared to 5 years ago, MDGL has more shares outstanding
The debt/assets ratio for MDGL has been reduced compared to a year ago.
MDGL Yearly Shares OutstandingMDGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
MDGL Yearly Total Debt VS Total AssetsMDGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 8.70 indicates that MDGL is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.70, MDGL belongs to the best of the industry, outperforming 81.24% of the companies in the same industry.
A Debt/Equity ratio of 0.54 indicates that MDGL is somewhat dependend on debt financing.
MDGL has a Debt to Equity ratio of 0.54. This is in the lower half of the industry: MDGL underperforms 72.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Altman-Z 8.7
ROIC/WACCN/A
WACC8.72%
MDGL Yearly LT Debt VS Equity VS FCFMDGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

A Current Ratio of 3.44 indicates that MDGL has no problem at all paying its short term obligations.
With a Current ratio value of 3.44, MDGL perfoms like the industry average, outperforming 40.34% of the companies in the same industry.
A Quick Ratio of 3.26 indicates that MDGL has no problem at all paying its short term obligations.
MDGL has a Quick ratio of 3.26. This is comparable to the rest of the industry: MDGL outperforms 41.28% of its industry peers.
Industry RankSector Rank
Current Ratio 3.44
Quick Ratio 3.26
MDGL Yearly Current Assets VS Current LiabilitesMDGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.60% over the past year.
The Revenue has grown by 864.21% in the past year. This is a very strong growth!
EPS 1Y (TTM)48.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.81%
Revenue 1Y (TTM)864.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%362.03%

3.2 Future

The Earnings Per Share is expected to grow by 37.70% on average over the next years. This is a very strong growth
MDGL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 85.80% yearly.
EPS Next Y56.73%
EPS Next 2Y48.88%
EPS Next 3Y45.44%
EPS Next 5Y37.7%
Revenue Next Year403.39%
Revenue Next 2Y188.84%
Revenue Next 3Y130.91%
Revenue Next 5Y85.8%

3.3 Evolution

MDGL Yearly Revenue VS EstimatesMDGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
MDGL Yearly EPS VS EstimatesMDGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 50 100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDGL. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 116.60 indicates a quite expensive valuation of MDGL.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MDGL indicates a rather cheap valuation: MDGL is cheaper than 87.24% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.39, MDGL is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 116.6
MDGL Price Earnings VS Forward Price EarningsMDGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGL Per share dataMDGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MDGL does not grow enough to justify the current Price/Earnings ratio.
MDGL's earnings are expected to grow with 45.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.88%
EPS Next 3Y45.44%

More info and screens

0

5. Dividend

5.1 Amount

MDGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (11/19/2025, 2:58:22 PM)

558.415

-0.58 (-0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners98.35%
Inst Owner Change2.1%
Ins Owners0.99%
Ins Owner Change-1.06%
Market Cap12.45B
Revenue(TTM)740.64M
Net Income(TTM)-289.13M
Analysts81.74
Price Target509.81 (-8.7%)
Short Float %18.15%
Short Ratio10.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-42.41%
Min EPS beat(2)-133.61%
Max EPS beat(2)48.79%
EPS beat(4)3
Avg EPS beat(4)-8.49%
Min EPS beat(4)-133.61%
Max EPS beat(4)48.79%
EPS beat(8)5
Avg EPS beat(8)-2.09%
EPS beat(12)6
Avg EPS beat(12)-1.21%
EPS beat(16)8
Avg EPS beat(16)-1.44%
Revenue beat(2)2
Avg Revenue beat(2)21.21%
Min Revenue beat(2)13.88%
Max Revenue beat(2)28.53%
Revenue beat(4)4
Avg Revenue beat(4)15.85%
Min Revenue beat(4)2.78%
Max Revenue beat(4)28.53%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.32%
PT rev (3m)17.71%
EPS NQ rev (1m)51.62%
EPS NQ rev (3m)66.51%
EPS NY rev (1m)6.53%
EPS NY rev (3m)29.34%
Revenue NQ rev (1m)12.19%
Revenue NQ rev (3m)54.36%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)28.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 116.6
P/S 16.81
P/FCF N/A
P/OCF N/A
P/B 19.89
P/tB 20.13
EV/EBITDA N/A
EPS(TTM)-12.89
EYN/A
EPS(NY)4.79
Fwd EY0.86%
FCF(TTM)-7.39
FCFYN/A
OCF(TTM)-7.2
OCFYN/A
SpS33.23
BVpS28.07
TBVpS27.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.22%
ROE -46.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.25%
FCFM N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 274.34%
Cap/Sales 0.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.44
Quick Ratio 3.26
Altman-Z 8.7
F-Score4
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)305.68%
Cap/Depr(5y)207.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.81%
EPS Next Y56.73%
EPS Next 2Y48.88%
EPS Next 3Y45.44%
EPS Next 5Y37.7%
Revenue 1Y (TTM)864.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%362.03%
Revenue Next Year403.39%
Revenue Next 2Y188.84%
Revenue Next 3Y130.91%
Revenue Next 5Y85.8%
EBIT growth 1Y43.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.64%
EBIT Next 3Y44.71%
EBIT Next 5YN/A
FCF growth 1Y45.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.97%
OCF growth 3YN/A
OCF growth 5YN/A

MADRIGAL PHARMACEUTICALS INC / MDGL FAQ

What is the ChartMill fundamental rating of MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MDGL.


What is the valuation status of MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

ChartMill assigns a valuation rating of 2 / 10 to MADRIGAL PHARMACEUTICALS INC (MDGL). This can be considered as Overvalued.


Can you provide the profitability details for MADRIGAL PHARMACEUTICALS INC?

MADRIGAL PHARMACEUTICALS INC (MDGL) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for MDGL stock?

The Earnings per Share (EPS) of MADRIGAL PHARMACEUTICALS INC (MDGL) is expected to grow by 56.73% in the next year.